Spots Global Cancer Trial Database for BRAF V600E Mutations In Papillary Thyroid Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: BRAF V600E Mutations In Papillary Thyroid Carcinoma

Official Title: Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma

Study ID: NCT01417442

Conditions

Papillary Thyroid Carcinoma

Interventions

BRAF V600E POSITIVITY

Study Description

Brief Summary: The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.

Detailed Description: Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.